KR20160035101A - 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물 - Google Patents

비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물 Download PDF

Info

Publication number
KR20160035101A
KR20160035101A KR1020167007395A KR20167007395A KR20160035101A KR 20160035101 A KR20160035101 A KR 20160035101A KR 1020167007395 A KR1020167007395 A KR 1020167007395A KR 20167007395 A KR20167007395 A KR 20167007395A KR 20160035101 A KR20160035101 A KR 20160035101A
Authority
KR
South Korea
Prior art keywords
cancer
carcinoma
treatment
leukemia
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167007395A
Other languages
English (en)
Korean (ko)
Inventor
베르나르뒤스 라데마케르
Original Assignee
코미녹스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코미녹스 인코포레이티드 filed Critical 코미녹스 인코포레이티드
Publication of KR20160035101A publication Critical patent/KR20160035101A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Luminescent Compositions (AREA)
KR1020167007395A 2005-05-09 2006-05-09 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물 Ceased KR20160035101A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05076071.9 2005-05-09
EP05076071A EP1721615A1 (en) 2005-05-09 2005-05-09 Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
PCT/KR2006/001731 WO2006121280A1 (en) 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157017831A Division KR20150085122A (ko) 2005-05-09 2006-05-09 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물

Publications (1)

Publication Number Publication Date
KR20160035101A true KR20160035101A (ko) 2016-03-30

Family

ID=35197739

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167007395A Ceased KR20160035101A (ko) 2005-05-09 2006-05-09 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물
KR1020157017831A Ceased KR20150085122A (ko) 2005-05-09 2006-05-09 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물
KR1020077028751A Expired - Fee Related KR101413731B1 (ko) 2005-05-09 2006-05-09 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의나트륨염 및 이것의 유도체를 함유하는 약학 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157017831A Ceased KR20150085122A (ko) 2005-05-09 2006-05-09 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물
KR1020077028751A Expired - Fee Related KR101413731B1 (ko) 2005-05-09 2006-05-09 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의나트륨염 및 이것의 유도체를 함유하는 약학 조성물

Country Status (23)

Country Link
US (2) US20090011047A1 (https=)
EP (5) EP1721615A1 (https=)
JP (1) JP5026408B2 (https=)
KR (3) KR20160035101A (https=)
CN (2) CN101277707A (https=)
AR (1) AR054448A1 (https=)
AU (1) AU2006244767B2 (https=)
BR (1) BRPI0608716A2 (https=)
CA (3) CA2840609C (https=)
CY (2) CY1113475T1 (https=)
DK (2) DK1885380T3 (https=)
ES (2) ES2394264T3 (https=)
HU (1) HUE046029T2 (https=)
IL (3) IL187220A (https=)
LT (1) LT3067068T (https=)
PL (2) PL1885380T3 (https=)
PT (1) PT1885380E (https=)
RU (1) RU2401662C2 (https=)
SG (5) SG177983A1 (https=)
SI (2) SI3067068T1 (https=)
TW (5) TWI386214B (https=)
WO (1) WO2006121280A1 (https=)
ZA (1) ZA200710559B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022035146A1 (ko) * 2020-08-12 2022-02-17 이상봉 탈모방지 또는 발모촉진용 외용제 조성물

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20120045520A1 (en) * 2008-08-21 2012-02-23 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
PT2475362T (pt) * 2009-09-10 2019-05-27 Kominox Inc Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos
BR112012008310A2 (pt) * 2009-09-18 2017-06-06 Kominox Inc métodos para tratamento de tumores cerebrais
WO2011086137A1 (en) 2010-01-13 2011-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Promyelocytic leukemia protein as a redox sensor
RU2602937C2 (ru) * 2011-01-11 2016-11-20 Универзитет Базель Комбинация сиросингопина и митохондриальных ингибиторов для лечения рака и для иммуносупрессии
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
KR101309844B1 (ko) * 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
RU2618405C1 (ru) * 2015-12-31 2017-05-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ определения продолжительности адъювантной химиотерапии при местно-распространенном колоректальном раке с метастазами в регионарные лимфоузлы после радикальных оперативных вмешательств
US10806768B2 (en) * 2016-05-26 2020-10-20 Stephen N. Pitcher Composition for promoting metallothionein production
ES2964979T3 (es) 2016-12-01 2024-04-10 Eupharma Pty Ltd Composiciones de arsénico
EP3758686B1 (en) 2018-02-26 2024-11-06 R.P. Scherer Technologies, LLC Pharmaceutical dosage form for an emulsion of simethicone and loperamide
AU2019239671B2 (en) * 2018-03-22 2025-02-27 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
WO2019234112A1 (en) * 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
IL295648A (en) * 2020-02-16 2022-10-01 Komipharm Int Australia Pty Ltd treatment method
KR20220020633A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 주사제 조성물
KR20220020637A (ko) * 2020-08-12 2022-02-21 이상봉 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물
CN112336746A (zh) * 2020-10-23 2021-02-09 内蒙古科技大学包头医学院 一种膀胱癌灌注化疗药物及其应用
CN116549741B (zh) * 2022-01-29 2025-04-11 中国科学院上海硅酸盐研究所 一种具有抑癌抗菌作用的表面改性镍钛合金材料及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
FR2431686A1 (fr) 1978-07-20 1980-02-15 Nestle Sa Soc Ass Tech Prod Mecanisme de dosage et d'equilibrage et machine de remplissage comprenant un tel mecanisme
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
KR930001917A (ko) * 1991-07-26 1993-02-22 김두석 악성 종양 치료제의 제조방법
EP0804928B1 (en) * 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
RU2035181C1 (ru) * 1994-02-18 1995-05-20 Тамара Васильевна Воробьева Средство для лечения лейкозов и способ лечения лейкозов
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
EP1496918B1 (en) * 2002-04-10 2023-02-08 Komipharm International Co., Ltd. Use of sodium meta-arsenite for the treatment of tumours
KR100632250B1 (ko) * 2004-02-16 2006-10-11 정태호 비소 화합물을 유효성분으로 하는 항암제
US20060104292A1 (en) 2004-11-15 2006-05-18 Gupta Vivek G System and methods for supporting multiple communications interfaces with single client interface
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
PT2475362T (pt) 2009-09-10 2019-05-27 Kominox Inc Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022035146A1 (ko) * 2020-08-12 2022-02-17 이상봉 탈모방지 또는 발모촉진용 외용제 조성물

Also Published As

Publication number Publication date
JP5026408B2 (ja) 2012-09-12
SI3067068T1 (sl) 2020-02-28
EP2361628A1 (en) 2011-08-31
IL187220A0 (en) 2008-02-09
SI1885380T1 (sl) 2013-01-31
PL1885380T3 (pl) 2013-02-28
TWI386214B (zh) 2013-02-21
SG10201602555WA (en) 2016-05-30
SG175633A1 (en) 2011-11-28
US20090011047A1 (en) 2009-01-08
TW201615200A (zh) 2016-05-01
CN101277707A (zh) 2008-10-01
LT3067068T (lt) 2019-12-10
SG10202100785PA (en) 2021-02-25
EP2762145A1 (en) 2014-08-06
IL229975A0 (en) 2014-01-30
TWI574692B (zh) 2017-03-21
CA2840609A1 (en) 2006-11-16
DK3067068T3 (da) 2019-11-18
KR101413731B1 (ko) 2014-07-10
ES2754372T3 (es) 2020-04-17
TW201500046A (zh) 2015-01-01
AU2006244767B2 (en) 2011-06-16
IL244728A0 (en) 2016-04-21
TWI522105B (zh) 2016-02-21
CA2926846A1 (en) 2006-11-16
KR20150085122A (ko) 2015-07-22
KR20080030559A (ko) 2008-04-04
CY1113475T1 (el) 2016-06-22
SG177983A1 (en) 2012-02-28
TW201540306A (zh) 2015-11-01
PL3067068T3 (pl) 2020-08-10
EP3067068A1 (en) 2016-09-14
US11464859B2 (en) 2022-10-11
IL187220A (en) 2014-11-30
TWI539957B (zh) 2016-07-01
TW201302208A (zh) 2013-01-16
BRPI0608716A2 (pt) 2010-12-07
HUE046029T2 (hu) 2020-01-28
EP3067068B1 (en) 2019-08-14
RU2007145489A (ru) 2009-06-20
WO2006121280A1 (en) 2006-11-16
AR054448A1 (es) 2007-06-27
CY1122522T1 (el) 2021-01-27
ES2394264T3 (es) 2013-01-30
RU2401662C2 (ru) 2010-10-20
EP1885380B1 (en) 2012-07-11
SG10201405278SA (en) 2015-05-28
CA2840609C (en) 2016-08-16
IL229975A (en) 2017-12-31
CN104758312A (zh) 2015-07-08
JP2008546640A (ja) 2008-12-25
EP1885380A1 (en) 2008-02-13
CA2926846C (en) 2019-04-02
EP1721615A1 (en) 2006-11-15
ZA200710559B (en) 2008-10-29
TW200716144A (en) 2007-05-01
DK1885380T3 (da) 2012-10-22
CA2608035C (en) 2015-02-17
US20160199411A1 (en) 2016-07-14
EP1885380A4 (en) 2009-02-18
CA2608035A1 (en) 2006-11-16
AU2006244767A1 (en) 2006-11-16
HK1109736A1 (en) 2008-06-20
PT1885380E (pt) 2012-10-11

Similar Documents

Publication Publication Date Title
KR101413731B1 (ko) 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의나트륨염 및 이것의 유도체를 함유하는 약학 조성물
KR20140033522A (ko) 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물
HK1109736B (en) Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
HK1096863A (en) Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
AU2011224052A1 (en) Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
HK1201043A1 (en) Sodium meta arsenite for use in the treatment of pain and/or inflammation associated with cancer
HK1161545A (en) Pharmaceutical compositions comprising of sodium meta-arsenite for use in the treatment of leukemia and lymphoma
KR20250126139A (ko) 종양을 치료하는 파클리탁셀 양이온성 리포솜의 용도

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160321

Application number text: 1020157017831

Filing date: 20150702

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160324

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160425

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170220

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160425

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20170522

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170220

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20180810

Appeal identifier: 2017101002485

Request date: 20170522

J301 Trial decision

Free format text: TRIAL NUMBER: 2017101002485; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170522

Effective date: 20180810

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20180810

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20170522

Decision date: 20180810

Appeal identifier: 2017101002485

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2018201007996; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20180810

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190712

Appeal identifier: 2018201007996

Request date: 20181008

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2018201007996; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20181008

Effective date: 20190712

PJ1302 Judgment (patent court)

Patent event date: 20190715

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20181008

Decision date: 20190712

Appeal identifier: 2018201007996

Appeal kind category: Appeal against decision to decline refusal